CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

Photo: Rob Acket/EMA

Pfizer's medicine candidate tanezumab is the only new medicine that the European Committee for Medicinal Products for Human Use (CMPH) is refusing to approve. This is clear from the highlights publicized after the committee's September meeting.

Tanezumab, also known as Raylumis, was intended as a treatment for pains associated with osteoarthritis, a form of arthritis, and is currently being evaluated by the US Food and Drug Administration (FDA), however in March of this year, an FDA advisory committee also voted against a recommendation of approval – 19 people against one.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs